{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:17:25Z","timestamp":1720689445884},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.3816\/clm.2007.s.015","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T21:06:16Z","timestamp":1221599176000},"page":"S145-S149","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S4","title":["Preclinical Rationale, Mechanisms of Action, and Clinical Activity of Anthracyclines in Myeloma"],"prefix":"10.3816","volume":"7","author":[{"given":"Mohamad A.","family":"Hussein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2007.s.015_bib1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence for a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib3","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4065\/81.7.889","article-title":"Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma","volume":"81","author":"Hussein","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2007.s.015_bib5","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib6","first-page":"133","article-title":"Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study","volume":"91","author":"Offidani","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2007.s.015_bib7","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"issue":"4 suppl 4","key":"10.3816\/CLM.2007.s.015_bib8","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminhematol.2005.10.003","article-title":"Lenalidomide: patient management strategies","volume":"42","author":"Hussein","year":"2005","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2007.s.015_bib9","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.015_bib10","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.015_bib11","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.015_bib12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or highdose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.015_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0014-4800(88)90002-0","article-title":"Dose-dependence of doxorubicin effect on actin assembly in vitro","volume":"49","author":"Colombo","year":"1988","journal-title":"Exp Mol Pathol"},{"key":"10.3816\/CLM.2007.s.015_bib14","first-page":"1975","article-title":"The effect of Adriamycin on the cell cycle traverse of a human lymphoid cell line","volume":"36","author":"Barlogie","year":"1976","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2007.s.015_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.015_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.2830350310","article-title":"New treatment strategies for multiple myeloma","volume":"35","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2007.s.015_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2007.s.015_bib18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","article-title":"Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma","volume":"2","author":"Samson","year":"1989","journal-title":"Lancet"},{"issue":"suppl 4","key":"10.3816\/CLM.2007.s.015_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"key":"10.3816\/CLM.2007.s.015_bib20","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2007.s.015_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.3816\/CLM.2007.s.015_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","article-title":"Clinical pharmacokinetics of doxorubicin","volume":"15","author":"Speth","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.3816\/CLM.2007.s.015_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.015_bib24","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"issue":"6 suppl 13","key":"10.3816\/CLM.2007.s.015_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.seminoncol.2004.08.005","article-title":"Role of liposomal anthracyclines in the treatment of multiple myeloma","volume":"31","author":"Hussein","year":"2004","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2007.s.015_bib26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bjc.6690070","article-title":"Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma","volume":"79","author":"Ribatti","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2007.s.015_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.2830500103","article-title":"Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44","volume":"50","author":"Vacca","year":"1995","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2007.s.015_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.s.015_bib29","first-page":"2540","article-title":"Kinetic response of human lymphoid cells to Adriamycin-DNA complex in vitro","volume":"36","author":"Barlogie","year":"1976","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2007.s.015_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000204489","article-title":"Effect of vincristine, Adriamycin and glucocorticoids on myeloma cells in vitro","volume":"89","author":"Chen","year":"1993","journal-title":"Acta Haematol"},{"key":"10.3816\/CLM.2007.s.015_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00001813-200311000-00004","article-title":"Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion","volume":"14","author":"Eucker","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CLM.2007.s.015_bib32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.s.015_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.015_bib34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib35","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.015_bib36","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.015_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.015_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1586\/14737140.5.1.25","article-title":"Thalidomide: present and future in multiple myeloma","volume":"5","author":"Hussein","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.3816\/CLM.2007.s.015_bib39","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib40","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib41","doi-asserted-by":"crossref","first-page":"124a","DOI":"10.1182\/blood.V108.11.124.124","volume":"108","author":"Orlowski","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.015_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-006-0220-3","article-title":"Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin","volume":"86","author":"Biehn","year":"2007","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T05:11:11Z","timestamp":1588914671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011701299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":42,"alternative-id":["S1557919011701299"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.s.015","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}